Collective licensing and asymmetric information: The double eff ect of the Medicine Patent Pool on generic drug markets

2021 ◽  
Author(s):  
Arianna Martinelli ◽  
Andrea Mina ◽  
Elena Romito
2012 ◽  
Vol 15 (4) ◽  
pp. A96
Author(s):  
B. Bian ◽  
E. Costea ◽  
C.M. Kelton ◽  
J.J. Guo ◽  
J. Boone

2017 ◽  
Vol 95 (3) ◽  
pp. 554-601 ◽  
Author(s):  
OLIVIER J. WOUTERS ◽  
PANOS G. KANAVOS ◽  
MARTIN McKEE

2010 ◽  
Vol 4 (1) ◽  
pp. 54-59 ◽  
Author(s):  
Li Liu ◽  
Hongzhou Lu

Unaffordable prices still bar the end-users in China from accessing ARV drugs. Patent protection of ARV drugs has dramatically limited the availability of these lifesaving drugs to AIDS patients in China. The way Chinese government can go to breakthrough the ARV drug patents are suggested as: -  Make more generic drugs available through compulsory licensing, impartment from other countries or building ARVs plants by partnerships between governments or generic drug companies. -  Do a thorough and detailed research on the patent application of ARV drugs to find out the loophole. -  Try patent pool to make AIDS medicines more affordable and appropriate for patients.


2012 ◽  
Vol 45 (17) ◽  
pp. 22
Author(s):  
ELIZABETH MECHCATIE
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document